Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
01/04/2026 13:02
April 1 (Reuters) - Cardiol Therapeutics Inc CRDL.TO: CARDIOL THERAPEUTICS - INITIATED PIVOTAL PHASE III MAVERIC TRIAL OF CARDIOLRX IN RECURRENT PERICARDITIS, SURPASSED 50% PATIENT ENROLLMENT CARDIOL THERAPEUTICS INC - PHASE III MAVERIC TRIAL OF CARDIOLRX FULL ENROLLMENT EXPECTED IN Q2 2026 Source text: [ID:n0001062993-26-001780] Further company coverage: CRDL.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM